Answers are grounded in this paper and cite their sources.
Chimeric antigen receptor macrophages (CAR-M) display superior tumor infiltration compared with CAR-T cells for solid tumor therapy, yet limited antitumor potency and antigen heterogeneity hinder their application. Direct engineering of chimeric antigen receptor monocytes (CAR-Mo) offers a simplified, cost-effective manufacturing alternative. Here, we engineered THP-1-derived monocytic cells with chimeric receptors containing FcRγ fused to phagocytosis-related cytoplasmic domains, targeting nucleolin and HER2. We constructed single-target and dual-antigen CAR-Mo platforms and evaluated their antitumor activity in vitro and in vivo . THP-1 monocytes carrying FcRγ-BAI1 or FcRγ-MERTK receptors exhibited enhanced phagocytosis, and dual-CAR-Mo achieved broader and stronger tumoricidal effects by targeting two tumor antigens. This dual-antigen-targeted CAR-Mo strategy activates both phagocytic and cytotoxic signaling pathways and represents a promising approach for solid tumor treatment. Collectively, this dual-target CAR-Mo strategy demonstrates promising antitumor efficacy in the THP-1 cell model, providing a feasible prototype for future optimization of solid tumor immunotherapy.
No takes yet. Share an insight, caveat, or question.
Su et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: